DTU Logo
About the DTU | News | Staff | Alumni | Contact/Find us

Ruth Coleman



Publications (20 of 20)


Search Publications :

In-press or Epub

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA
Diabet Med. 2017. Epub:23-Oct-2017. PMID:29057545. doi:10.1111/dme.13533

Baseline Characteristics and Temporal Differences in Acarbose Cardiovascular Evaluation (ACE) Trial Participants
Michael J. Theodorakis, Ruth L. Coleman, Huimei Feng, Juliana Chan, Jean-Louis Chiasson, Junbo Ge, Hertzel C. Gerstein, Yong Huo, Zhihui Lang, John J. McMurray, Lars Rydén, Stefan Schröder, Michal Tendera, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan and Rury R. Holman for the ACE Study Group
Am Heart J 2017. Epub:10-Sep-2017. doi:10.1016/j.ahj.2017.09.001

2017

Health selection into neighborhoods among patients enrolled in a clinical trial
Mariana Arcaya, Ruth L. Coleman, Fahad Razak, Maria L. Alva, Rury R. Holman
Preventive Medicine Reports 2017;8:51–54. Published:Dec-2017. Epub:28-Jul-2017. doi:10.1016/j.pmedr.2017.07.003

Effects of Acarbose on Cardiovascular and Diabetes Outcomes in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: A Randomised Controlled Trial
Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan for the ACE Study Group
Lancet Diabetes Endocrinol. 2017;5:877-86. Published:Nov-2017. Epub:13-Sep-2017. PMID:28917545. doi:10.1016/S2213-8587(17)30309-1
[Slides] [Slides #2]

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis
Rakesh Malhotra, Hoang Anh Nguyen, Oscar Benavente, Mihriye Mete, Barbara Howard, Jonathan Mant, Michelle C. Odden, Carmen A. Peralta, Alfred Cheung, Girish Nadkarni, Ruth L. Coleman, Rury R. Holman, Alberto Zanchetti, Ruth Peters, Nigel Beckett, Jan Staessen, Joachim H. Ix
JAMA Intern Med 2017;177:1498-1505. Published:Oct-2017. Epub:05-Sep-2017. PMID:28873137. doi:10.1001/jamainternmed.2017.4377

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group
Lancet Diabetes Endocrinol. 2017;5:431-437. Published:Jun-2017. Epub:29-Mar-2017. PMID:28365411. doi:10.1016/S2213-8587(17)30104-3

2016

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
Kaixin Zhou, Sook Wah Yee, Eric L Seiser, Nienke van Leeuwen, Roger Tavendale, Amanda J Bennett, Christopher J Groves, Ruth L Coleman, Amber A van der Heijden, Joline W Beulens, Catherine E de Keyser, Linda Zaharenko, Daniel M Rotroff, Mattijs Out, Kathleen A Jablonski, Ling Chen, Martin Javorsky?, Jozef Židzik, Albert M Levin, L Keoki Williams, Tanja Dujic, Sabina Semiz, Michiaki Kubo, Huan-Chieh Chien, Shiro Maeda, John S Witte, Longyang Wu, Ivan Tkác?19, Adriaan Kooy, Ron H N van Schaik, Coen D A Stehouwer, Lisa Logie, MetGen Investigators, DPP Investigators, ACCORD Investigators, Calum Sutherland, Janis Klovins, Valdis Pirags, Albert Hofman, Bruno H Stricker, Alison A Motsinger-Reif, Michael J Wagner, Federico Innocenti, Leen M ’t Hart, Rury R Holman, Mark I McCarthy, Monique M Hedderson, Colin N A Palmer, Jose C Florez, Kathleen M Giacomini & Ewan R Pearson
Nature Genetics 2016;48:1055-9. Published:Sep-2016. Epub:08-Aug-2016. PMID:27500523. doi:10.1038/ng.3632

Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes
M.A. Bethel, P Harrison, H Sourij, Y Sun, L Tucker, I Kennedy , S White, L Hill, A Oulhaj, R Coleman, R.R. Holman
Diabetic Medicine 2016;33:224-230. Published:Feb-2016. Epub:14-Jul-2015. PMID:26043186. doi:10.1111/dme.12828

2014

Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83)
T. M. E. Davis, R. L. Coleman and R. R. Holman for the UKPDS Group
Diabetic Medicine 2014;31:200-207. Published:Feb-2014. Epub:22-Nov-2013. PMID:24267048. doi:10.1111/dme.12353

2013

Evaluation of a Self-Administered Oral Glucose Tolerance Test
M. Angelyn Bethel, Hermione C. Price, Harald Sourij, Sarah White, Ruth L. Coleman, Arne Ring, Irene E. C. Kennedy, Lynne Tucker, and Rury R. Holman
Diabetes Care 2013;36:1483-1488. Published:Jun-2013. Epub:15-Jan-2013. PMID:23321216. doi:10.2337/dc12-0643

Prognostic Significance of Silent Myocardial Infarction in Newly-Diagnosed Type 2 Diabetes: UKPDS 79
Timothy M.E. Davis; Ruth L. Coleman; Rury R. Holman
Circulation 2013;127:980-987. Published:05-Mar-2013. Epub:29-Jan-2013. PMID:23362315. doi:10.1161/CIRCULATIONAHA.112.000908

2009

Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al.
Paul S, Coleman RL, Price HC, Farmer AJ
Diabetes Care 2009;32:e60. Published:May-2009. PMID:19407070. doi:10.2337/dc09-0183
[Abstract]

Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw K, Wareham NJ, Griffin SJ
Diabetes Care 2009;32:708-713. Published:Apr-2009. Epub:29-Dec-2008. PMID:19114615. doi:10.2337/dc08-1918
[Abstract]

Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes
Price HC, Coleman RL, Stevens RJ, Holman RR
Diabetologia 2009;52:394-397. Published:Mar-2009. Epub:02-Dec-2008. PMID:19048226. doi:10.1007/s00125-008-1231-5
[Abstract]

2007

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting
The Mount Hood 4 Modeling Group
Diabetes Care 2007;30:1638-1646. Published:Jun-2007. PMID:17526823. doi:10.2337/dc07-9919

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes
Ruth L. Coleman, Richard J. Stevens, Ravi Retnakaran, and Rury R. Holman
Diabetes Care 2007;30:1292-1293. Published:May-2007. Epub:08-Feb-2007. PMID:17290036. doi:10.2337/dc06-1358

2005

Non-HDL Cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes
Holman RR, Coleman RL, Shine BS, Stevens RJ
Diabetes Care 2005;28:1796-1797. Published:Jul-2005. PMID:15983339. doi:10.2337/diacare.28.7.1796

Framingham risk equations underestimate coronary heart disease risk in diabetes
R. J. Stevens, R. L. Coleman, R. R. Holman
Diabetic Medicine 2005;22:228. Published:Feb-2005. Epub:19-Jan-2005. PMID:15660747. doi:10.1111/j.1464-5491.2005.01387.x

2004

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR
Diabetes Care 2004;27:201-207. Published:Jan-2004. PMID:14693990. doi:10.2337/diacare.27.1.201
[Abstract]